Alan J Russell

CSO Alan J Russell sold 200,000 shares ($7.9M) on 2026-07-01 per 10b5-1 plan; retains 24,555 non-derivative + 1,077,717 options.

Alan J Russell, Chief Scientific Officer at Edgewise Therapeutics, executed 2 separate sales totaling 200,000 shares for $7,881,401.98 at $39.41 per share on 2026-07-01 as part of a pre-arranged 10b5-1 trading plan. His non-derivative holdings fell from 224.6K shares to 24.6K shares (-89.1%), though he retains 1,077,717 option shares (Table II), so his overall equity exposure remains material. Edgewise is unprofitable (net income $-49.0M over the most recent fiscal year) and trades at $39.56 currently, -10.0% from its 52-week high of $43.93. His prior 5 sales at EWTX have tracked mixed outcomes: the most recent (2025-11-12) saw 90-day post-sale appreciation of +46.8%, while the 2024-12-30 sale declined -15.0% over 90 days, showing no clear directional bias for timing accuracy at this ticker. Because this transaction is scheduled under a 10b5-1 plan rather than discretionary, it does not convey a tactical judgment about price or company direction.

Chief Scientific Officer Russell Alan J sold 100,000 shares (81.0% of holdings) at $21.12; stock down 43.9% from 52-week high, company unprofitable.

Russell Alan J executed a substantial 100,000-share sale at $21.12 on 2025-11-12, reducing his stake from 123,400 to 23,400 shares (an 81.0% reduction). The transaction occurred against mixed context: while the stock has surged 38.9% over 30 days and 44.3% over 90 days, it remains 43.9% below its 52-week high of $36.38 and trades at $20.42 currently. At the same ticker (EWTX), Russell has executed 5 prior open-market sales; his timing track record there shows mixed results, with 1 of 4 measurable 90-day outcomes well-timed (negative post-sale return). Edgewise reported a negative net income of $-40,666,000.00 over its most recent full fiscal year. The magnitude of the position reduction—81.0% of prior holdings—and the company's unprofitable status warrant attention to whether this reflects a material shift in Russell's assessment of the opportunity.

Chief Scientific Officer Russell Alan J sells 100,000 shares of EWTX at $14.60, reducing stake 81.0%, as stock trades 60.0% below 52-week high.

Russell Alan J, Chief Scientific Officer, sold 100,000 shares (100.0K shares) at $14.60, totaling $1,459,760.00 ($1.5M), reducing his post-transaction holdings to 23,400 shares (23.4K shares) from 123,400 shares (123.4K shares)—a net change of sold 100,000 shares (-81.0% vs pre-transaction holdings). The sale occurs as EWTX trades -60.0% from 52-week high of $36.62 and the company reported net income of $-36,115,000.00 ($-36.1M), indicating continued unprofitability. His prior trades at EWTX show mixed timing outcomes: 1 of 4 prior sells were well-timed at the 90-day mark, with the most recent sale on 2024-12-30 yielding a 90d return of -15.0% (well-timed) but earlier sales producing positive 90d returns. The magnitude of this reduction—divesting 81.0% of holdings—against a backdrop of significant stock depreciation and ongoing losses warrants attention to whether the insider views near-term prospects as constrained.

Russell Alan J (CSO) sold 100,000 EWTX shares at $27.37; stock now $26.70, down 19.1% in 30 days.

Chief Scientific Officer Russell Alan J executed a substantial sale of 100,000 shares (87.1% of pre-transaction holdings) at $27.37 on 2024-12-30, reducing his stake to 14,863 shares. The sale occurred at a price above the current market level of $26.70, though the stock has declined 19.1% over the past 30 days and trades 27.1% below its 52-week high of $36.62. His prior three sales at EWTX showed mixed results: two September 2024 sales captured 20.6%–25.9% gains over 30 days, but his December 2023 sale yielded 71.5% over 90 days—suggesting he has historically exited positions before sustained declines at this ticker. The company is unprofitable (net income $-34,129,000.00) and trades at a $2.5B market cap, creating potential pressure on high-conviction insiders. This substantial reduction in CSO holdings coincides with near-term downward price momentum and the insider's historical pattern of exits preceding further losses.

CSO Russell Alan J sold 75,000 shares (75.0K) at blended $28.27, reducing holdings 85.5% to 12.7K shares

Russell Alan J, Chief Scientific Officer, executed 2 separate sales on 2024-09-20 totaling 75,000 shares (75.0K shares) for $2,120,101.19, reducing his holdings from 87.7K to 12.7K shares—a reduction of 85.5% of his pre-transaction position. The sale occurred at a blended average price of $28.27, which is now 8.8% above the current price of $25.92 and near the 52-week high of $29.50. The company remains unprofitable with net income of $-31,497,000.00 over its most recent full fiscal year. His prior sell at this ticker (2023-12-26) did not achieve favorable timing, with the 90-day return showing positive movement rather than the decline that would indicate a well-timed exit, and his cross-ticker track record shows 0.00% well-timed rate on prior sells.